Healthcare provider profile · identity verified

Scott Stratton-Smith, MD

Family Practice · ROCHESTER, NY · NPI 1750318515

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	469	181
Lisinopril	Lisinopril	341	114
Levothyroxine Sodium	Levothyroxine Sodium	315	95
Gabapentin	Gabapentin	213	59
Hydrochlorothiazide	Hydrochlorothiazide	196	67
Rosuvastatin Calcium	Rosuvastatin Calcium	175	62
Amlodipine Besylate	Amlodipine Besylate	168	61
Omeprazole	Omeprazole	146	55
Pantoprazole Sodium	Pantoprazole Sodium	144	49
Sertraline Hcl	Sertraline Hcl	140	47
Escitalopram Oxalate	Escitalopram Oxalate	131	30
Metoprolol Succinate	Metoprolol Succinate	128	41
Losartan Potassium	Losartan Potassium	119	49
Albuterol Sulfate Hfa	Albuterol Sulfate	110	34
Simvastatin	Simvastatin	107	35
Metformin Hcl	Metformin Hcl	106	35
Trazodone Hcl	Trazodone Hcl	106	32
Metformin Hcl Er	Metformin Hcl	92	33
Fluticasone Propionate	Fluticasone Propionate	91	27
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	91	30
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	84	17
Zolpidem Tartrate	Zolpidem Tartrate	83	16
Meloxicam	Meloxicam	78	29
Eliquis	Apixaban	71	18
Clonazepam	Clonazepam	69	19
Tamsulosin Hcl	Tamsulosin Hcl	68	26
Fluoxetine Hcl	Fluoxetine Hcl	66	21
Felodipine Er	Felodipine	65	18
Atenolol	Atenolol	59	21
Metoprolol Tartrate	Metoprolol Tartrate	59	29
Glipizide Er	Glipizide	58	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	56	19
Pravastatin Sodium	Pravastatin Sodium	54	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	49	17
Oxycodone Hcl	Oxycodone Hcl	49	suppressed
Allopurinol	Allopurinol	45	14
Furosemide	Furosemide	45	16
Duloxetine Hcl	Duloxetine Hcl	42	13
Venlafaxine Hcl Er	Venlafaxine Hcl	42	suppressed
Bupropion Xl	Bupropion Hcl	41	13
Hydroxyzine Hcl	Hydroxyzine Hcl	40	13
Diazepam	Diazepam	38	15
Irbesartan	Irbesartan	37	suppressed
Buspirone Hcl	Buspirone Hcl	36	11
Famotidine	Famotidine	36	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	11
Prednisone	Prednisone	34	29
Glipizide	Glipizide	33	11
Amoxicillin	Amoxicillin	32	19
Montelukast Sodium	Montelukast Sodium	32	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	31	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	30	suppressed
Baclofen	Baclofen	29	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	28	suppressed
Tramadol Hcl	Tramadol Hcl	28	12
Mirtazapine	Mirtazapine	27	suppressed
Promethazine Hcl	Promethazine Hcl	27	suppressed
Carvedilol	Carvedilol	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	11
Lorazepam	Lorazepam	24	11
Fludrocortisone Acetate	Fludrocortisone Acetate	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Ozempic	Semaglutide	22	suppressed
Warfarin Sodium	Warfarin Sodium	22	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Alendronate Sodium	Alendronate Sodium	20	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Finasteride	Finasteride	19	suppressed
Meclizine Hcl	Meclizine Hcl	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	suppressed
Celecoxib	Celecoxib	17	suppressed
Mometasone Furoate	Mometasone Furoate	17	suppressed
Mounjaro	Tirzepatide	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Potassium Chloride	Potassium Chloride	16	suppressed
Torsemide	Torsemide	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Lovastatin	Lovastatin	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Cephalexin	Cephalexin	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error